OROlga Renner

Olga Renner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Renner has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of Vaginal Microbiota and Oral Lactobacillus Supplementation in Recurrent Urinary Tract Infections of Menopausal Women: Protocol for the VaMirUTI Cohort Study

    by Dimitri Barski, Patrick Finzer, Klaus Golka, Olga Renner, Ralph Wirtz, Thorsten Ecke, Thomas Otto

    (1) Background: Recurrent urinary tract infections (rUTIs) are common among peri- and postmenopausal women, partly due to hormonal changes that disrupt the vaginal microbiota. A reduction in Lactobacillus dominance is associated with increased risk of rUTI. Although antibiotics remain the standard of care, their use contributes to the emergence of multidrug-resistant pathogens. Probiotics may offer a non-antibiotic alternative; however, clinical evidence remains limited. (2) Methods: The VaMirUTI study is a prospective, monocentric, non-randomized cohort investigating the combined effect of oral probiotics and vaginal estriol on vaginal and urinary microbiota in peri- and postmenopausal women with recurrent UTIs. The primary endpoints are (i) change in Lactobacillus dominance at 3 months and (ii) UTI recurrence at 12 months. A total of 100 women (70 rUTI, 30 controls) will be followed for up to 12 months. Vaginal swabs and urine samples will be collected at baseline, during UTI episodes, and at study completion. Vaginal microbiota composition will be analyzed by 16S rRNA gene sequencing. (3) Results: This protocol outlines the study design and methodology. The primary outcome is the change in vaginal Lactobacillus dominance following the intervention. Secondary outcomes include UTI recurrence rates and the identification of microbiota signatures associated with rUTI. (4) Conclusions: The VaMirUTI study will clarify the relationship between vaginal microbiota, oral probiotic supplementation, and rUTI in menopausal women, potentially informing future non-antibiotic preventive strategies.


  • Open Access

    The therapeutic potential of vitamins A, C, and D in pancreatic cancer

    by Alban Piotrowsky, Markus Burkard, Hendrik Schmieder, Sascha Venturelli, Olga Renner, Luigi Marongiu


  • Open Access

    Analysis of High-Dose Ascorbate-Induced Cytotoxicity in Human Glioblastoma Cells and the Role of Dehydroascorbic Acid and Iron

    by Alban Piotrowsky, Markus Burkard, Katharina Hammerschmidt, Hannah K. Ruple, Pia Nonnenmacher, Monika Schumacher, Christian Leischner, Susanne Berchtold, Luigi Marongiu, Thomas A. Kufer, et al.

    Several studies have demonstrated, both in vitro and in animal models, the anti-tumor efficacy of high-dose ascorbate treatment against a variety of tumor entities, including glioblastoma, the most common and aggressive primary malignant brain tumor. The aim of this study was to investigate the effects of high-dose ascorbate as well as dehydroascorbic acid on human glioblastoma cell lines and to evaluate different treatment conditions for the combined administration of ascorbate with magnesium (Mg2+) and iron (Fe3+). Intracellular levels of reactive oxygen species and the induction of cell death following ascorbate treatment were also investigated. We demonstrated high cytotoxicity and antiproliferative efficacy of high-dose ascorbate in human glioblastoma cells, whereas much weaker effects were observed for dehydroascorbic acid. Ascorbate-induced cell death was independent of apoptosis. Both the reduction in cell viability and the ascorbate-induced generation of intracellular reactive oxygen species could be significantly increased by incubating the cells with Fe3+ before ascorbate treatment. This work demonstrates, for the first time, an increase in ascorbate-induced intracellular ROS formation and cytotoxicity in human glioblastoma cells by pre-treatment of the tumor cells with ferric iron, as well as caspase-3 independence of cell death induced by high-dose ascorbate. Instead, the cell death mechanism caused by high-dose ascorbate in glioblastoma cells shows evidence of ferroptosis. The results of the present work provide insights into the efficacy and mode of action of pharmacological ascorbate for the therapy of glioblastoma, as well as indications for possible approaches to increase the effectiveness of ascorbate treatment.